NCT03381755 is a Phase 4 clinical trial of half-dose ticagrelor in Acute Coronary Syndrome, sponsored by First Affiliated Hospital of Harbin Medical University.

Who is sponsoring NCT03381755?

NCT03381755 is sponsored by First Affiliated Hospital of Harbin Medical University.

What drugs are being tested in NCT03381755?

Interventions in NCT03381755: half-dose ticagrelor, standard-dose ticagrelor.

What condition does NCT03381755 study?

NCT03381755 studies Acute Coronary Syndrome.

Is NCT03381755 still recruiting?

NCT03381755 is currently status unknown. Last updated 12 September 2018.

Last reviewed 2018-09-12 · How we verify

NCT03381755

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI

Status unknown Phase 4 Last updated 12 September 2018

What this trial tests

Phase 4 trial testing half-dose ticagrelor in Acute Coronary Syndrome in 200 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
14 December 2019

14 December 2020

Quick facts

Lead sponsor	First Affiliated Hospital of Harbin Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	200
Start date	1 January 2018
Primary completion	14 December 2019
Estimated completion	14 December 2020
Sites	1 location across China

Drugs / interventions tested

half-dose ticagrelor — full drug profile →
standard-dose ticagrelor — full drug profile →

Conditions studied

Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →

Sponsor

First Affiliated Hospital of Harbin Medical University

Who can join

Adults 18 to 75, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor. Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But the effectiveness and safety of low-dose ticagrelor remain yet not very clearly in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting

Other First Affiliated Hospital of Harbin Medical University trials

Trials by the same sponsor.

NCT07020195 — QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease · NA · not yet recruiting
NCT06975592 — Study on the Mechanism of Multi-group Analysis of the Influence of Depression on Common Cardiovascular Diseases · not yet recruiting
NCT06995456 — Multivariate Analysis and Prediction of Hypertensive Disorder Complicating Pregnancy and Its Related Mechanism · not yet recruiting
NCT07087093 — Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly · NA · recruiting
NCT06565845 — Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03381755 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Harbin Medical University
Last refreshed: 12 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03381755.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing